UNSPSC 51183112: Thiohexamide

This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 6M8CV4TKXL. European Medicines Agency schedules Thiohexamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10979MIG. Thiohexamide generally arises in the molecular formula C14H20N2O3S2.

UNSPSC 51183112 Thiohexamide is a Commodity code describing a specific pharmaceutical active ingredient, but the recent state and local contracting activity shows that this code is being used to solicit generic multi-source pharmaceuticals and over-the-counter products more broadly. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 for manufacturers to supply comprehensive generic pharmaceutical and OTC product lines through established wholesale distribution channels. State and local governments procure under this code to stock pharmacy shelves, clinical supplies, and medical facilities across participating jurisdictions. The solicitation required vendors to provide detailed product specifications including National Drug Codes, SKUs, and UPCs, demonstrating that the actual buying activity encompasses complete pharmaceutical product portfolios rather than single-ingredient compounds. Vendors must hold current Good Manufacturing Practices (cGMP) certification, comply with the Drug Supply Chain Security Act (DSCSA), and maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson Co., LLC). Issuing bodies are state agencies and participating local government facilities within cooperative purchasing networks.

MMCAP's RFP, due March 26, 2026, covers Minnesota and Oregon jurisdictions. The procurement model awards single, dual, or multiple vendors based on therapeutic considerations and member-specific needs, with contract terms of two years for new responders (effective July 1, 2026) and optional extensions. Evaluation weighted price competitiveness at 75 percent, with the remaining 25 percent split among fixed pricing certainty, administrative fee format compliance, EDI capability, and pricing-structure flexibility (flat price, net price variants, or WAC-minus formats). No specific set-aside designations were noted. The solicitation required all products to be available in the marketplace by May 15, 2026, with a cutoff date for vendor questions on February 18, 2026. Vendors must carry commercial general liability insurance of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, and all products must hold FDA compliance and minimum six-month shelf life from manufacture.